Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06827054 · ClinicalTrials.gov registry record · Phase 2
Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids
A Phase 2 study, sponsored by Roswell Park Cancer Institute.
- Not yet
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT06827054 is a Phase 2 study that has not yet begun recruiting, run by Roswell Park Cancer Institute. The registered enrollment target is 20 participants.
The verdict
NCT06827054, a Phase 2 study, has not yet begun recruiting, sponsored by Roswell Park Cancer Institute.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This phase II trial studies whether psilocybin with psychotherapy is safe and if it works for improving chronic pain in cancer patients who require opioids to manage their pain. Psilocybin is taken from the mushroom Psilocybe mexicana. Psilocybin acts on the brain to cause hallucinations (sights, sounds, smells, tastes, or touches that a person believes to be real but are not real). This may impact a patient's "total pain", a view that accounts for the psychological, spiritual, and social factors that contribute to their experience of pain. Psychotherapy uses methods such as discussion, listening, and counseling to help patients change the way they react to environmental triggers that may cause a negative reaction. Giving psilocybin with psychotherapy may be safe and helpful for improving chronic pain in cancer patients who require opioids to manage their pain.
Interventions
- PROCEDURE Biospecimen Collection
- BEHAVIORAL Psychotherapy
- OTHER Interview
- PROCEDURE Functional Magnetic Resonance Imaging
- DRUG Psilocybine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-08-15 |
| Est. Completion | 2027-05-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06827054
The ClinicalTrials.gov registry entry for NCT06827054 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT06827054 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06827054 about?
NCT06827054 is a clinical study titled "Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids". This phase II trial studies whether psilocybin with psychotherapy is safe and if it works for improving chronic pain in cancer patients who require opioids to manage their pain. Psilocybin is taken from the mushroom Psilocybe mexicana. Psilocybin acts on the brain to cause hallucinations (sights, so...
What is the current status of trial NCT06827054?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2026-08-15. Estimated completion is 2027-05-05.
What interventions are being tested in trial NCT06827054?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Psychotherapy (BEHAVIORAL), Interview (OTHER), Functional Magnetic Resonance Imaging (PROCEDURE), Psilocybine (DRUG).
Who is sponsoring clinical trial NCT06827054?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.